Image copyright GSK Image caption Flint Flints ill days were brought back to life in 2017 after inhaling toxic lead-contaminated water
A panel of medical experts in the US has approved new vaccines for adults who take part in childhood immunisations.
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) said COVID-19, made by GlaxoSmithKline, was effective.
It will be available to the general population, who will need to go through their healthcare provider first.
The news comes a week after the FDA approved four new booster vaccines for children aged six months to eight years.
Once they are seen by a healthcare provider they will receive the vaccines, which protect against two viruses, two bacteria and one vaccine against pneumococcal disease.
In the cases of COVID-19 and GlaxoSmithKline’s vaccine Vaxigrip v3 (for adults), both should be given in the same step-two package, before a booster for infants.
Both vaccines have been approved for use in children – 12 to 17 months.
When it comes to adults, however, the key task for healthcare providers will be to determine which of these vaccines is best for each individual.
Experts say the most effective and effective vaccines for adults are those that don’t cause adverse effects.
Amanda Schuermann, an immunisation expert at the CDC said: “The committee decided that the most appropriate timing for use of the COVID-19 vaccines is 12 months after the last dose of DTaP or DTaP +.
“The timing for the Vaxigrip vaccines will depend on the schedule of healthcare providers who administer Pneumococcal and influenza vaccines.
“We don’t know how long the Tdap booster, which is needed for women expecting a child, will be required before new booster vaccines are given.
“If patients were planning to give birth, they would be advised to receive a new booster Tdap vaccination.”